News
Empowering the biopharma industry with field-leading foundation models.
Recent News
Press
|
August 24, 2023
Genesis Therapeutics raises $200 million for AI-aided drug discovery
C&EN
Press
|
August 22, 2023
Genesis Therapeutics scores $200 million for AI drug discovery
San Francisco Business Times
Press
|
August 21, 2023
Genesis Therapeutics raises $200M for AI drug discovery based on Stanford research
Endpoints News
Press
|
August 21, 2023
WSJ: Andreessen Co-Leads $200 Million Investment in Biotech Startup Genesis Therapeutics
WSJ
Press
|
August 21, 2023
AI drug designer Genesis Therapeutics forges $200M round with eye on clinical testing
Fierce Biotech
Press
|
August 21, 2023
Genesis Therapeutics Closes Oversubscribed $200M Series B
Business Wire
Press
|
May 6, 2022
AI 50 2022: North America's Top AI Companies Shaping The Future
Forbes
Press
|
April 30, 2021
Genesis Therapeutics Hires Will McCarthy as Chief Business Officer
Business Wire
Join Us
Opportunities in AI and Physics Research
Our molecular AI research team is pioneering new frameworks for drug discovery, at the intersection of multi-dimensional ML models and physical simulation. See opportunities in software engineering, machine learning and computation chemistry.
Software Engineering
Machine Learning
Computational Chemistry
